Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#1
REVIEW
Giulia Marvaso, Barbara Alicja Jereczek-Fossa, Mattia Zaffaroni, Maria Giulia Vincini, Giulia Corrao, Nicolaus Andratschke, Ehsan H Balagamwala, Jens Bedke, Oliver Blanck, Umberto Capitanio, Rohann J M Correa, Gert De Meerleer, Ciro Franzese, Aurora Gaeta, Sara Gandini, Cristina Garibaldi, Peter C Gerszten, Silke Gillessen, William R Grubb, Matthias Guckenberger, Raquibul Hannan, Pavan M Jhaveri, Mirjana Josipovic, Linda G W Kerkmeijer, Eric J Lehrer, Magnus Lindskog, Alexander V Louie, Quynh-Nhu Nguyen, Piet Ost, David A Palma, Giuseppe Procopio, Maddalena Rossi, Michael Staehler, Alison C Tree, Yat Man Tsang, Nicholas Van As, Nicholas G Zaorsky, Thomas Zilli, David Pasquier, Shankar Siva
The purpose of this European Society for Radiotherapy and Oncology (ESTRO) project, endorsed by the European Association of Urology, is to explore expert opinion on the management of patients with oligometastatic and oligoprogressive renal cell carcinoma by means of stereotactic ablative radiotherapy (SABR) on extracranial metastases, with the aim of developing consensus recommendations for patient selection, treatment doses, and concurrent systemic therapy. A questionnaire on SABR in oligometastatic renal cell carcinoma was prepared by a core group and reviewed by a panel of ten prominent experts in the field...
May 2024: Lancet Oncology
#2
JOURNAL ARTICLE
Paolo Morgagni, Maria Bencivenga, Fatima Carneiro, Stefano Cascinu, Sarah Derks, Maria Di Bartolomeo, Claire Donohoe, Clarisse Eveno, Suzanne Gisbertz, Peter Grimminger, Ines Gockel, Heike Grabsh, Paulo Kassab, Rupert Langer, Sara Lonardi, Marco Maltoni, Sheraz Markar, Markus Moehler, Daniele Marrelli, Maria Antonietta Mazzei, Davide Melisi, Carlo Milandri, Paul Stefan Moenig, Bianca Mostert, Gianni Mura, Wojciech Polkowski, John Reynolds, Luca Saragoni, Mark I Van Berge Henegouwen, Richard Van Hillegersberg, Michael Vieth, Giuseppe Verlato, Lorena Torroni, Bas Wijnhoven, Guido Alberto Massimo Tiberio, Han-Kwang Yang, Franco Roviello, Giovanni de Manzoni
BACKGROUND: Many gastric cancer patients in Western countries are diagnosed as metastatic with a median overall survival of less than twelve months using standard chemotherapy. Innovative treatments, like targeted therapy or immunotherapy, have recently proved to ameliorate prognosis, but a general agreement on managing oligometastatic disease has yet to be achieved. An international multi-disciplinary workshop was held in Bertinoro, Italy, in November 2022 to verify whether achieving a consensus on at least some topics was possible...
April 18, 2024: Gastric Cancer
#3
EDITORIAL
D Shor, V Khoo, K T Jayaprakash
No abstract text is available yet for this article.
March 26, 2024: Clinical Oncology: a Journal of the Royal College of Radiologists
#4
JOURNAL ARTICLE
Seong Hee Yeo, Hyun Jung Yoon, Injoong Kim, Yeo Jin Kim, Young Lee, Yoon Ki Cha, So Hyeon Bak
PURPOSE: To develop models to predict programmed death ligand 1 (PD-L1) expression in pulmonary squamous cell carcinoma (SCC) using CT. MATERIALS AND METHODS: A total of 97 patients diagnosed with SCC who underwent PD-L1 expression assay were included in this study. We performed a CT analysis of the tumors using pretreatment CT images. Multiple logistic regression models were constructed to predict PD-L1 positivity in the total patient group and in the 40 advanced-stage (≥ stage IIIB) patients...
March 2024: J Korean Soc Radiol
#5
JOURNAL ARTICLE
Tianming Wang, Liang Zhang, Ying Cheng
The therapeutic landscape of advanced non-small cell lung cancer (NSCLC) has been significantly improved by developing immunotherapy represented by programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1) immune checkpoint inhibitors (ICI). Furthermore, immunotherapy combined with chemotherapy is an essential treatment strategy for driver-negative advanced NSCLC, especially in a population with PD-L1 <50%, and leads to long-term survival in the entire population regardless of the PD-L1 expression status...
April 8, 2024: Chinese Clinical Oncology
#6
JOURNAL ARTICLE
Shuang Huang, Feng Jiang, Caineng Cao, Qifeng Jin, Ting Jin, Yonghong Hua, Xiaozhong Chen
PURPOSE: We conducted a single-center, single-arm study (NCT03129412) to prospectively analyze the long-term outcomes of newly diagnosed patients with oligometastatic nasopharyngeal carcinoma (NPC) who received radical radiotherapy and local treatment of metastases. PATIENTS AND METHODS: Patients who reached disease controll after platinum-based palliative chemotherapy continued to receive radical radiotherapy for the nasopharyngeal region and neck. Appropriate local treatments were selected to treat the metastatic lesions...
April 5, 2024: Radiotherapy and Oncology
#7
JOURNAL ARTICLE
S Armstrong, A Makris, K Belessiotis-Richards, M Abdul-Latif, P Ostler, N Shah, D Miles, Y M Tsang
AIMS: Evidence shows stereotactic ablative body radiotherapy (SABR) is used as a non-invasive ablative therapy in the treatment of multisite oligometastatic (OM) and oligoprogressive (OP) diseases originating from metastatic breast cancer. This study aims to report the treatment outcomes and to investigate what factors that are prognostic in terms of local control, progression-free survival (PFS) and overall survival (OS) in patients receiving SABR for extracranial OM and OP diseases originating from metastatic breast cancer...
March 19, 2024: Clinical Oncology: a Journal of the Royal College of Radiologists
#8
JOURNAL ARTICLE
J Chamois, A L Septans, B Schipman, E Gross, N Blanchard, V Passerat, C Debelleix, C G Hemery, I Latorzeff, Y Pointreau
Oligometastases are defined as a number of detectable metastases less or equal to 5. In castrate-resistant oligo metastatic prostate Cancer (CR oligoM PC), Metastases-Directed Ablative radiotherapy (MDRT) is poorly investigated. Our study retrospectively reviewed the cases of CR oligoM PC treated with MDRT in 8 French high-volume radiotherapy centers. OS and PFS are defined as the delay between the first day of MDRT and death (OS) or progression according to PCWG criteria (PFS). OS and PFS are evaluated according to Kaplan Meyer, curves are compared with log rank test...
May 2024: Clinical and Translational Radiation Oncology
#9
REVIEW
Alexander J Grosinger, Sara R Alcorn
PURPOSE OF REVIEW: Increasing life expectancy among patients with advanced cancer has placed a greater emphasis on optimizing pain control and quality of life. Concurrently, significant advancements in radiotherapy for bone metastases have permitted for dose escalation strategies such as stereotactic radiotherapy. This review aims to provide updated information on the management of bone metastases in light of these developments. RECENT FINDINGS: We reviewed recent studies regarding the role and details of external beam radiotherapy for bone metastases, with emphasis on differences by treatment site as well as intention (palliative versus ablative for oligometastases)...
March 28, 2024: Current Oncology Reports
#10
JOURNAL ARTICLE
D Franceschini, C Franzese, T Comito, M B Ilieva, R Spoto, A M Marzo, L Dominici, M Massaro, L Bellu, M Badalamenti, P Mancosu, M Scorsetti
BACKGROUND AND PURPOSE: To report mature results for local control and survival in oligometastatic (OM) breast cancer patients treated with stereotactic body radiotherapy (SBRT) on lung and/or liver lesions in a phase II trial. METHODS: This is a prospective non-randomized phase II trial (NCT02581670) which enrolled patients from 2015 to 2021. Eligibility criteria included: age > 18 years, ECOG 0-2, diagnosis of breast cancer, maximum of 4 lung/liver lesions (with a maximum diameter < 5 cm), metastatic disease confined to the lungs and liver or extrapulmonary or extrahepatic disease stable or responding to systemic therapy...
March 22, 2024: Radiotherapy and Oncology
#11
JOURNAL ARTICLE
Victorine Trentesaux, Sophie Maiezza, Emilie Bogart, Marie-Cécile Le Deley, Emmanuel Meyer, Ludovic Vanquin, David Pasquier, Laurent Mortier, Xavier Mirabel
INTRODUCTION: Stereotactic radiotherapy (SBRT) potentially has a role in the management of oligometastatic melanoma. However, literature with data specific to this management is very limited. The objectives of this study were to evaluate the time to local control (LC) of extra-cranial melanoma metastases after SBRT treatment and to help establish if SBRT is a useful therapy for oligometastatic melanoma. METHODS: A retrospective study was conducted with data collected from two referral centers in France between 2007 and 2020...
2024: Frontiers in Oncology
#12
JOURNAL ARTICLE
Siyao Mai, Haiqing Liu, Hong Zeng, Ziliang Cheng, Jingwen Huang, Guangzi Shi, Yong Li, Zhuo Wu
BACKGROUND: The aim of this study was to compare breast cancer patients with pulmonary oligometastases (POM) and primary lung cancer (PLC) and to assess whether there were differences in clinical features, CT features, and survival outcomes between the two groups. METHODS: From January 2010 to December 2021, the clinical records of 437 with malignant pulmonary nodules who had breast cancer patients were reviewed. POM was identified in 45 patients and PLC in 43 patients after the initial detection of pulmonary nodules...
March 18, 2024: Thoracic Cancer
#13
JOURNAL ARTICLE
Adam Mutsaers, Ahmed Abugharib, Ian Poon, Joshua Loblaw, Andrew Bayley, Liying Zhang, Lee Chin, Madette Galapin, Darby Erler, Arjun Sahgal, Kevin Higgins, Danny Enepekides, Antoine Eskander, Irene Karam
PURPOSE: To report clinical outcomes for patients with metastatic disease to the head and neck (HN) treated with stereotactic body radiation therapy (SBRT). METHODS: A retrospective review of patients treated with SBRT to HN sites from 2012 to 2020 was conducted. Treatment indications included the following: oligometastases, oligoprogression, and control a dominant area of progression (DAP). Kaplan-Meier method was used to estimate local control (LC), regional control (RC), overall survival (OS), and progression-free survival (PFS)...
March 15, 2024: Supportive Care in Cancer
#14
REVIEW
Adam Mutsaers, Aquila Akingbade, Alexander V Louie, Badr Id Said, Liying Zhang, Ian Poon, Martin Smoragiewicz, Antoine Eskander, Irene Karam
INTRODUCTION: Stereotactic body radiotherapy (SBRT) is increasingly used to treat disease in the oligometastatic (OM) setting due to mounting evidence demonstrating its efficacy and safety. Given the low population representation in prospective studies, we performed a systematic review and meta-analysis of outcomes of HNC patients with extracranial OM disease treated with SBRT. METHODS: A systematic review was conducted with Cochrane, Medline, and Embase databases queried from inception to August 2022 for studies with extracranial OM HNC treated with stereotactic radiotherapy...
February 20, 2024: Cancers
#15
JOURNAL ARTICLE
Billy Down, Svetlana Lakunina, Nick Maynard, Sheraz R Markar, Alex Gordon-Weeks
Oligometastatic oesophagogastric cancer was recently defined by consensus as the presence of no more than two metastases and an 18-week period of oncological stability during chemotherapy. The number of patients who fit this criterion and whether their oncological outcome differs from those with multi-metastatic disease is unknown. We analysed a database of 497 patients from 2017 to 2021 with metastatic oesophageal cancer. In total, 36 (7.2%) had oligometastatic disease and significantly improved median overall survival (mOS) versus multi-metastatic disease...
April 2024: European Journal of Surgical Oncology
#16
JOURNAL ARTICLE
Akshat Saxena, Jack Andrews, Alan Haruo Bryce, Irbaz Bin Riaz
PURPOSE OF REVIEW: Low-volume prostate cancer is an established prognostic category of metastatic hormone-sensitive prostate cancer. However, the term is often loosely used to reflect the low burden of disease across different prostate cancer states. This review explores the definitions of low-volume prostate cancer, biology, and current evidence for treatment. We also explore future directions, including the impact of advanced imaging modalities, particularly prostate-specific membrane antigen (PSMA) positron emission tomography (PET) scans, on refining patient subgroups and treatment strategies for patients with low-volume prostate cancer...
March 6, 2024: Current Opinion in Urology
#17
MULTICENTER STUDY
Gang Wang, Zhigang Wei, Feihang Wang, Xiaoying Han, Haipeng Jia, Danyang Zhao, Chunhai Li, Lingxiao Liu, Xia Yang, Xin Ye
BACKGROUND: Pulmonary oligometastases are common in hepatocellular carcinoma (HCC), however, the existing therapeutic options have several limitations. This study aimed to assess the safety and efficacy of microwave ablation (MWA) in the treatment of HCC-originating pulmonary oligometastases. METHODS: A total of 83 patients, comprising 73 males and 10 females with a median age of 57 years, who had pulmonary oligometastases from HCC, underwent MWA treatment at four different medical institutions...
March 4, 2024: Cancer Imaging: the Official Publication of the International Cancer Imaging Society
#18
JOURNAL ARTICLE
María-Carmen Rubio Rodríguez, Xin Chen-Zhao, Ovidio Hernando, Sonia Flamarique, Pedro Fernández-Letón, Maider Campo, Mercedes López, Maitane Rodríguez, Daniel Zucca, Daniel Martínez, Emilio Sánchez-Saugar, Fernando Mañeru, Juan García Ruiz-Zorrilla, Paz García de Acilu, Jeannette Valero, Angel Montero, Raquel Ciérvide, Beatriz Alvarez, Mariola García-Aranda, Rosa Alonso, Miguel Angel de la Casa, Leyre Alonso, Mónica Nuñez, Jaime Martí, Fernando Arias
OBJECTIVE: This study aimed to assess the efficacy and tolerability of stereotactic body radiation therapy (SBRT) for the treatment of liver metastases. METHODS: Patients with up to 5 liver metastases were enrolled in this prospective multicenter study and underwent SBRT. Efficacy outcomes included in-field local control (LC), progression-free survival (PFS), and overall survival (OS). Acute and late toxicities were evaluated using CTCAE v.4.0. RESULTS: A total of 52 patients with 105 liver metastases were treated between 2015 and 2018...
March 2, 2024: Clinical & Translational Oncology
#19
JOURNAL ARTICLE
Reina Maeda, Tadahiko Shien, Mina Takahashi, Kengo Kawada, Yukiko Kajiwara, Shinichiro Kubo, Daisuke Takabatake, Shoichiro Ohtani, Kinya Matsuoka, Hajime Hikino, Yutaka Ogasawara, Naruto Taira, Shozo Osumi, Masahiko Ikeda, Hiroyoshi Doihara
While local treatment of metastases is considered to be unrelated to prognosis, previous studies have suggested that local treatment of isolated lung metastases may have positive prognostic impact. We designed this prospective cohort study to investigate the clinical situation and its outcomes. We enrolled patients with fewer than 3 lung nodules suspected of being oligometastases after curative breast cancer surgery. Treatments, including local and systemic therapy, were selected by the physician and patient in consultation...
February 2024: Acta Medica Okayama
#20
EDITORIAL
Hangcheng Fu
No abstract text is available yet for this article.
2024: Frontiers in Medicine
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
